ADC trials are moving from binary antigen testing to quantitative, multiparameter biomarker models that better predict efficacy and toxicity.
Bea Mann
Advertisement
Bea Mann, PhD, is head of Oncology Drug Development Services on ADC biomarkers at ICON.
Articles by Bea Mann
Advertisement
Latest Updated Articles
Refining Biomarker-Based Patient Selection for ADC TrialsOctober 30th 2026
Advertisement
Advertisement
Trending on BioPharm International
1
FDA Finalizes Potency Assurance Guidance for Cell and Gene Therapies
2
Shilpa CDMO Commits $50 Million to Scale Peptide Capacity in India
3
Lonza to Acquire Merck KGaA’s US CDMO Business, Adding ADC, Viral Vector, and LNP Capacity
4
Teva Licenses US Rights to Samsung Bioepis TNF Inhibitor Biosimilars
5